Velesco expands core scientific and quality team

Appoints director of quality and senior pharmaceutical scientist

Contract research organisation Velesco Pharmaceutical Services, which operates from facilities in Plymouth and Kalamazoo, Michigan, US, has added Shirley Smith as director of quality and Yuan Chen as senior pharmaceutical scientist.

Prior to joining Velesco, Smith was quality assurance manager for Richard-Allan Scientific and senior quality assurance manager for Pfizer’s Drug Product and Device Research Group in Kalamazoo, MI.

In conjunction with her role at Velesco, Smith will continue her leadership position at PharmaMed Resources, a quality assurance and regulatory affairs consultancy that services the Medical Device and Pharmaceutical Industries.

Chen has extensive experience in analytical methods development and validation, cleaning verification and validation, and drug release testing.

Before joining Velesco, Chen served in the Pharmaceutical Sciences Division of Pfizer Global R&D as a senior associate scientist for eight years and the Analytical Development Department of Caraco Pharmaceutical Laboratories for two years. Her experience spans the drug development spectrum from early stage development and validation of stability-indicating methods for the release of drug substance and drug product, to later stage projects focused on the detection of residual drugs on manufacturing equipment.

You may also like

Research & Development

Velesco Pharma expands and opens new cGMP-compliant analytical testing laboratory

Increases the breadth of its services to meet client needs
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Subscribe now